What Is a Good HDL Cholesterol Level? What Low HDL Actually Means.

HDL occupies an unusual position in cardiovascular medicine: its association with cardiovascular events is strong and consistent, yet the interventions that raise it pharmacologically do not reduce those events. That gap between epidemiology and pharmacology tells clinicians something important. HDL is a marker of cardiovascular health, not a direct protective mechanism that can be targeted in isolation.

If your doctor circled a low HDL on your lipid panel and handed it back to you without much explanation, you are not alone. Low HDL is one of the most commonly noted and least carefully explained findings in primary care. The number is real, the risk signal it carries is real, and the path forward is specific. What it does not mean is that you need a drug to push the number up.

The Mechanism

High-density lipoprotein is a lipoprotein particle produced by the liver and intestine that participates in reverse cholesterol transport, the movement of excess cholesterol from peripheral tissues and arterial walls back to the liver for elimination or bile secretion. The long-standing hypothesis was that higher HDL would accelerate removal of cholesterol from atherosclerotic plaques, slowing or reversing plaque accumulation. That hypothesis shaped decades of drug development.

The particle itself is not a simple container. HDL is functionally heterogeneous: it includes multiple subclasses that differ in size, density, lipid composition, and protein cargo. The most cardioprotective properties attributed to HDL include anti-inflammatory signaling, antioxidant effects mediated by the enzyme paraoxonase-1, endothelial nitric oxide stimulation, and anti-apoptotic effects on vascular cells. The problem is that the HDL number on a standard lipid panel reflects total cholesterol mass carried in HDL particles. It does not measure HDL particle function, HDL particle number, or which HDL subclasses are present. A high HDL number does not guarantee high HDL function.

This distinction matters enormously. In certain genetic conditions such as CETP deficiency, HDL levels are dramatically elevated but the particles are dysfunctional and cardiovascular risk is not reduced. Conversely, individuals with very low HDL caused by loss-of-function mutations in ABCA1 (Tangier disease) have severe HDL deficiency but do not consistently show the expected degree of cardiovascular risk elevation. These genetic observations were early signals that HDL mass and HDL function are separable, and that mass is the less important of the two.

The observational association, however, is real and well-established. Low HDL (below 40 mg/dL in men, below 50 mg/dL in women) is consistently associated with higher cardiovascular event rates across large prospective cohort studies. The Framingham Heart Study established HDL as one of the strongest independent predictors of coronary heart disease risk in the general population over multiple decades of follow-up. Every 1 mg/dL decrease in HDL was associated with a 2 to 3 percent increase in coronary heart disease risk in the Framingham data. 5 / Solid

The association also survives adjustment for LDL, triglycerides, and most traditional cardiovascular risk factors, which made it an appealing drug target. The reasoning was straightforward: if high HDL is associated with lower risk in observational data, raising HDL should lower risk. This reasoning turned out to be wrong.

HDL as a Window Into Your Metabolic State

Before covering the pharmacology failures, it is worth being precise about what low HDL is telling you when it appears on your panel. In the vast majority of men, low HDL is not a primary genetic disorder. It is a downstream consequence of one or more of the following conditions.

Insulin resistance and visceral adiposity. When the liver is handling excess calories and producing large amounts of VLDL (very low-density lipoprotein), the resulting triglyceride-rich environment accelerates HDL catabolism. The liver pulls HDL particles out of circulation faster, and the plasma HDL level falls. A man with a 40-inch waist and mildly elevated fasting glucose who has HDL of 34 mg/dL is not suffering primarily from an HDL problem. He is suffering from a metabolic problem that is expressing itself partly as a low HDL.

Physical inactivity. Skeletal muscle activity upregulates lipoprotein lipase and hepatic lipase pathways that influence HDL metabolism. The HERITAGE Family Study, which enrolled 675 sedentary adults in a standardized 20-week aerobic exercise program, found that men with the lowest baseline fitness showed the largest HDL response to training, with sedentary men averaging 6 to 8 mg/dL lower HDL than active counterparts at baseline. The mechanism involves increased ApoA-I synthesis and reduced triglyceride-rich lipoprotein competition for HDL precursors.

Active tobacco use. Smoking increases oxidative stress, impairs HDL’s antioxidant capacity, and directly suppresses HDL production. In a 2013 meta-analysis in Preventive Medicine covering 54 cross-sectional studies and over 250,000 participants, active smokers had HDL values averaging 4.7 mg/dL lower than never-smokers. The suppression reverses: HDL begins rising within 2 to 4 weeks of cessation and approaches full recovery within 1 year.

Refined carbohydrate and trans fat intake. High carbohydrate diets, particularly those driven by refined grains and added sugars, suppress HDL through increased VLDL production and accelerated HDL clearance. Trans fatty acids from partially hydrogenated vegetable oils lower HDL and raise LDL simultaneously. The diet-HDL relationship is more nuanced than a single intervention; replacing refined carbohydrates with monounsaturated or polyunsaturated fats tends to raise HDL, but the effect size is modest compared to exercise.

Understanding which of these drivers is active for you determines what the response should be. A man with low HDL because he smokes a pack a day and a man with low HDL who runs 25 miles a week but carries visceral fat need different interventions, even if their HDL numbers are identical.

What the Evidence Shows

The systematic attempt to pharmacologically raise HDL and reduce cardiovascular events is one of the more instructive episodes in modern cardiology. Multiple drug classes, multiple trials, and a consistent pattern of failure.

CETP inhibitors are the most striking example. Cholesteryl ester transfer protein (CETP) transfers cholesterol from HDL to LDL. Blocking CETP raises HDL dramatically. The first-in-class agent, torcetrapib, raised HDL by 72 percent in the ILLUMINATE trial of 15,067 patients. The trial was stopped early because torcetrapib increased cardiovascular mortality and total mortality. The drug had off-target effects on aldosterone and blood pressure that explained part of the harm, but the principle that raising HDL was itself sufficient to reduce events was disproven for that agent. Barter et al., NEJM 2007.

The CETP inhibitor program continued with cleaner compounds. Dalcetrapib, tested in the dal-OUTCOMES trial of 15,871 patients, raised HDL by 31 percent with no off-target effects, and produced no reduction in cardiovascular events whatsoever. Schwartz et al., NEJM 2012. Evacetrapib, tested in the ACCELERATE trial of 12,092 high-risk patients, raised HDL by 130 percent and also produced no cardiovascular benefit. Anacetrapib, the most potent CETP inhibitor tested, raised HDL by approximately 100 percent and produced a modest reduction in cardiovascular events in the REVEAL trial, but that benefit was attributed entirely to the LDL-lowering it produced, not the HDL elevation.

Niacin was the second major HDL-raising drug class tested. Niacin raises HDL substantially (15 to 35 percent depending on dose) and was widely used before the large trials reported. The AIM-HIGH trial randomized 3,414 patients with established cardiovascular disease already on statin therapy to extended-release niacin versus placebo. Niacin raised HDL by 25 percent, reduced triglycerides, and produced zero reduction in cardiovascular events. The trial was stopped early for futility. Boden et al., NEJM 2011.

HPS2-THRIVE enrolled 25,673 patients on statin therapy and assigned them to extended-release niacin plus laropiprant (a drug to reduce flushing) or placebo. Niacin again raised HDL and lowered triglycerides, and again produced no reduction in cardiovascular events. It increased serious adverse events including myopathy, new-onset diabetes, and infections. Landray et al., NEJM 2014.

These failures have a common interpretation: the low HDL seen in observational studies is a marker of the underlying metabolic state (insulin resistance, physical inactivity, visceral adiposity, tobacco use) that drives cardiovascular risk. The HDL number itself is not the mechanism through which risk is transmitted. Raising the number without changing the underlying state does not change events.

Mendelian randomization studies, which use naturally occurring genetic variants that raise or lower HDL to test causal relationships, have generally supported this interpretation. Genetic variants that raise HDL do not consistently lower cardiovascular risk, in contrast to genetic variants that lower LDL, which do. Voight et al., Lancet 2012.

The Triglycerides-to-HDL Ratio: The Number Your Doctor Should Mention

The ratio of triglycerides to HDL is more informative than either number alone. Divide your fasting triglycerides by your HDL, both in mg/dL. A ratio below 2.0 is associated with a favorable metabolic profile. A ratio above 3.0 signals the atherogenic dyslipidemia pattern: elevated ApoB particle burden, small-dense LDL predominance, and an insulin-resistant metabolic background. A ratio above 5.0 warrants direct clinical attention.

The 2004 Quebec Cardiovascular Study, which followed 2,072 men for 5 years, found that a triglycerides-to-HDL ratio above 4.0 was the single strongest predictor of ischemic heart disease in their cohort, outperforming LDL alone, total cholesterol, and several other standard markers. The ratio tracked closely with dense LDL particle size, which is the mechanistically dangerous phenotype. Lamarche et al., Arteriosclerosis, Thrombosis, and Vascular Biology 1996.

This ratio is particularly useful because it identifies men whose LDL may appear acceptable on a standard panel while their actual atherogenic particle burden is elevated. The man with LDL of 110, triglycerides of 190, and HDL of 36 has a ratio of 5.3. His standard panel looks borderline. His cardiologist should be paying close attention to ApoB and considering a coronary artery calcium score.

The ratio also responds to the same interventions that raise HDL: aerobic exercise, reduction of refined carbohydrates, weight loss, and smoking cessation. In most cases, addressing the drivers of low HDL will simultaneously lower triglycerides, and the ratio will improve faster than HDL alone.

ApoB: The Metric That Matters More

ApoB is the structural protein present on every atherogenic lipoprotein particle: LDL, VLDL, IDL, and Lp(a). Because each particle carries exactly one ApoB molecule, measuring ApoB counts the total atherogenic particle burden in circulation.

The metabolic state that produces low HDL also tends to produce an elevated ApoB independent of LDL. Insulin resistance drives VLDL overproduction in the liver; as VLDL is metabolized, it produces remnant particles and small-dense LDL, each carrying its own ApoB. Total ApoB rises even when LDL cholesterol mass appears normal.

The 2019 European Society of Cardiology guidelines concluded that ApoB is a more reliable primary lipid target than LDL for risk stratification in patients with elevated triglycerides, diabetes, insulin resistance, or obesity. Mach et al., European Heart Journal 2020. These are exactly the patients who tend to present with low HDL.

If your HDL is low and your physician has never mentioned ApoB, ask for it at your next visit. The test is inexpensive and available through any standard laboratory.

What to Do This Week

1. Pull your last lipid panel and calculate your triglycerides-to-HDL ratio. Divide triglycerides by HDL (both in mg/dL). A ratio above 3.0 indicates you are expressing the atherogenic lipid phenotype that low HDL is part of. Bring this calculation to your next physician visit.

2. If your HDL is below 40 mg/dL, treat the number as a signal pointing to four possible drivers: physical inactivity, active tobacco use, excess visceral fat, or a high refined-carbohydrate diet. Identify which of those applies and address it directly. The HDL will follow.

3. Start or increase regular aerobic exercise. Meta-analyses of exercise intervention trials consistently show HDL increases of 3 to 9 percent with structured aerobic training, with the effect appearing at both moderate and vigorous intensities. This is the single most effective evidence-based intervention for raising HDL. Kodama et al., Archives of Internal Medicine 2007.

4. If you smoke, cessation is the most important step you can take for HDL specifically and cardiovascular risk broadly. Active smoking suppresses HDL by approximately 5 mg/dL. That suppression reverses within 2 to 4 weeks of cessation.

5. Ask your physician to order ApoB if it is not already on your lipid panel. If your ApoB is above 90 mg/dL and your HDL is below 40, that combination warrants a concrete treatment plan, not a recheck in a year.

6. If you snore or have daytime fatigue and have never been evaluated for obstructive sleep apnea, mention it to your physician. Untreated sleep apnea worsens insulin resistance and produces the same dyslipidemia pattern that causes low HDL.

7. Do not pursue pharmacological HDL elevation. The trial evidence against this approach is consistent across multiple large trials. If a supplement is promoted on the basis of raising your HDL number, the evidence does not support that claim.

The evidence on HDL points in one direction: behavioral changes that improve metabolic health raise HDL as a byproduct of lowering overall cardiovascular risk. Raising HDL as an end in itself, particularly through pharmacological means, does not appear to provide independent cardiovascular benefit. Low HDL is a window into the metabolic state beneath it, and the metabolic state is where the work happens.

The Signal Check is fifteen questions mapping the cardiovascular risk pattern across the physiological domains most commonly missed in standard screenings. It produces a specific starting point for your next clinical conversation.